Literature DB >> 25358541

Hydrops, fetal pleural effusions and chylothorax in three patients with CBL mutations.

Luzie Bülow1, Christina Lissewski, Rainer Bressel, Anita Rauch, Zornitza Stark, Martin Zenker, Oliver Bartsch.   

Abstract

Fetal hydrops, fetal pleural effusions, hydrothorax, and chylothorax, may be associated with various genetic disorders, in particular with the Noonan, cardio-facio-cutaneous and Costello syndromes. These syndromes, collectively called RASopathies, are caused by mutations in the RAS/MAPK pathway, which is known to play a major role in lymphangiogenesis. Recently, germline mutations in the Casitas B-cell lymphoma (CBL) gene were reported in 25 patients and of these, 20 had juvenile myelomonocytic leukemia (JMML). The disorder was named "CBL syndrome" or "Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia" (NSLL). To date, prenatal abnormalities have not been reported and it is still debated whether the CBL syndrome falls into the category of a RASopathy, or represents a different entity. Here we report on three unrelated patients with CBL mutations manifesting with hydrops fetalis, fetal pleural effusions and/or congenital hydro-/chylothorax. Our findings further connect the CBL syndrome with the RASopathies.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CBL gene; Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (OMIM #613563); RASopathy; congenital hydrothorax or chylothorax; hydrops

Mesh:

Substances:

Year:  2014        PMID: 25358541     DOI: 10.1002/ajmg.a.36838

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

Review 1.  A system-based approach to the genetic etiologies of non-immune hydrops fetalis.

Authors:  Anne H Mardy; Shilpa P Chetty; Mary E Norton; Teresa N Sparks
Journal:  Prenat Diagn       Date:  2019-06-26       Impact factor: 3.050

2.  ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.

Authors:  Dong Li; Michael E March; Alvaro Gutierrez-Uzquiza; Charlly Kao; Christoph Seiler; Erin Pinto; Leticia S Matsuoka; Mark R Battig; Elizabeth J Bhoj; Tara L Wenger; Lifeng Tian; Nora Robinson; Tiancheng Wang; Yichuan Liu; Brant M Weinstein; Matthew Swift; Hyun Min Jung; Courtney N Kaminski; Rosetta Chiavacci; Jonathan A Perkins; Michael A Levine; Patrick M A Sleiman; Patricia J Hicks; Janet T Strausbaugh; Jean B Belasco; Yoav Dori; Hakon Hakonarson
Journal:  Nat Med       Date:  2019-07-01       Impact factor: 53.440

3.  Lymphangiography as a Treatment for Refractory Congenital Chylothorax Due to RASopathies: A Report of Two Cases.

Authors:  Naoya Kinota; Hiroshi Kodama; Taiki Moriyama; Junichi Taniguchi; Mitsunari Maruyama; Atsushi Ogasawara; Yasukazu Kako; Kaoru Kobayashi; Haruyuki Takaki; Akio Shibata; Kyoko Minagawa; Yasuhiro Takeshima; Koichiro Yamakado
Journal:  Interv Radiol (Higashimatsuyama)       Date:  2022-01-12

Review 4.  Lymphatic Abnormalities in Noonan Syndrome Spectrum Disorders: A Systematic Review.

Authors:  Julia Sleutjes; Lotte Kleimeier; Erika Leenders; Willemijn Klein; Jos Draaisma
Journal:  Mol Syndromol       Date:  2021-09-10

Review 5.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

Review 6.  Genetic Disorders with Predisposition to Paediatric Haematopoietic Malignancies-A Review.

Authors:  Aleksandra Filipiuk; Agata Kozakiewicz; Kamil Kośmider; Monika Lejman; Joanna Zawitkowska
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

7.  Casitas B-lineage lymphoma Gene Mutation Ocular Phenotype.

Authors:  Christine Fardeau; Munirah Alafaleq; Marie-Adélaïde Ferchaud; Miguel Hié; Caroline Besnard; Sonia Meynier; Frédéric Rieux-Laucat; Damien Roos-Weil; Fleur Cohen; Isabelle Meunier
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.